Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease

Biochemical Society Transactions

Volumn 38, Issue 6, 2010, Pages 1453-1457

  D'Azzo, Alessandra ^a   Bonten, Erik ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Glycoprotein; Glycosphingolipid; Lysosomal storage disease (LSD); Neuramidase 1 (NEU1); Pathogenesis; Protective protein cathepsin A (PPCA)

Indexed keywords

BETA GALACTOSIDASE; CARBOXYPEPTIDASE; CARBOXYPEPTIDASE C; GANGLIOSIDE GM1; GLYCOSIDASE; GLYCOSPHINGOLIPID; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NEURAMIDASE 1; PROTECTIVE PROTEIN CATHEPSIN A; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CONFERENCE PAPER; ENZYME REPLACEMENT; GENE THERAPY; GM1 GANGLIOSIDOSIS; LIPIDOSIS; LYSOSOME STORAGE DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PURKINJE CELL; SIALIDOSIS; STORAGE DISEASE;

ANIMALS; BETA-GALACTOSIDASE; CATHEPSIN A; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; GLYCOSPHINGOLIPIDS; HUMANS; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; MODELS, MOLECULAR; MULTIENZYME COMPLEXES; NEURAMINIDASE; PROTEIN CONFORMATION;

EID: 78649720042     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0381453     Document Type: Conference Paper

References (35)

1. Pshezhetsky, A. and Potier, M. (1996) Association of N- acetylgalactosamine-6-sulfate sulfatase with the multienzyme lysosomal complex of β-galactosidase, cathepsin A, and neuraminidase. J. Biol. Chem. 271, 28359-28365
2. van der Spoel, A., Bonten, E. and d'Azzo, A. (1998) Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A. EMBO J. 17, 1588-1597
3. Yamamoto, Y. and Nishimura, K. (1987) Copurification and separation of β-galactosidase and sialidase from porcine testis. Int. J. Biochem. 19, 435-442
4. Zhou, X.Y., Morreau, H., Rottier, R., Davis, D., Bonten, E., Gillemans, N., Wenger, D., Grosveld, F.G., Doherty, P., Suzuki, K., Grosveld, G.C. and d'Azzo, A. (1995) Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells. Genes Dev. 9, 2623-2634
5. Galjart, N.J., Gillemans, N., Harris, A., van der Horst, G.T., Verheijen, F.W., Galjaard, H. and d'Azzo, A. (1988) Expression of cDNA encoding the human "protective protein" associated with lysosomal β-galactosidase and neuraminidase: homology to yeast proteases. Cell 54, 755-764
6. Jackman, H.L., Morris, P.W., Deddish, P.A., Skidgel, R.A. and Erdös, E.G. (1992) Inactivation of endothelin I by deamidase (lysosomal protective protein). J. Biol. Chem. 267, 2872-2875
7. Rudenko, G., Bonten, E., d'Azzo, A. and Hol, W.G. (1995) Three-dimensional structure of the human 'protective protein': structure of the precursor form suggests a complex activation mechanism. Structure 3, 1249-1259
8. Bonten, E.J., Campos, Y., Zaitsev, V., Nourse, A., Waddell, B., Lewis, W., Taylor, G. and d'Azzo, A. (2009) Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization. J. Biol. Chem. 284, 28430-28441
9. d'Azzo, A., Andria, G., Strisciuglio, P. and Galjaard, H. (2001) Galactosialidosis. In The Metabolic and Molecular Bases of Inherited Disease (Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D., eds), pp. 3811-3826, McGraw-Hill, New York
10. Itoh, K., Oyanagi, K., Takahashi, H., Sato, T., Hashizume, Y., Shimmoto, M. and Sakuraba, H. (2000) Endothelin-1 in the brain of patients with galactosialidosis: its abnormal increase and distribution pattern. Ann. Neurol. 47, 122-126
11. Leimig, T., Mann, L., Martin Mdel, P., Bonten, E., Persons, D., Knowles, J., Allay, J.A., Cunningham, J., Nienhuis, A.W., Smeyne, R. and d'Azzo, A. (2002) Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood 99, 3169-3178
12. Jackman, H.L., Tan, F.L., Tamei, H., Buerling-Harbury, C., Li, X.Y., Skidgel, R.A. and Erdös, E.G. (1990) A peptidase in human platelets that deamidates tachykinins: probable identity with the lysosomal "protective protein". J. Biol. Chem. 265, 11265-11272
13. Jackman, H.L., Massad, M.G., Sekosan, M., Tan, F., Brovkovych, V., Marcic, B.M. and Erdös, E.G. (2002) Human heart tissue enzymes cleave angiotensin (Ang) I to release Ang 1-9, Ang II, or Ang 1-7. Hypertension 39, 976-981
14. Seyrantepe, V., Hinek, A., Peng, J., Fedjaev, M., Ernest, S., Kadota, Y., Canuel, M., Itoh, K., Morales, C.R., Lavoie, J., Tremblay, J. and Pshezhetsky, A.V. (2008) Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation. 117, 1973-1981
15. Schauer, R. (2004) Sialic acids: fascinating sugars in higher animals and man. Zoology 107, 49-64
16. Bonten, E., Van Der Spoel, A., Fornerod, M., Grosveld, G. and d'Azzo, A. (1996) Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev. 10, 3156-3169
17. Manzoni, M., Colombi, P., Papini, N., Rubaga, L., Tiso, N., Preti, A., Venerando, B., Tettamanti, G., Bresciani, R., Argenton, F. et al. (2007) Molecular cloning and biochemical characterization of sialidases from zebrafish (Danio rerio). Biochem J. 408, 395-406
18. Thomas, G.H. (2001) Disorders of glycoprotein degradation and structure: α-mannosidosis, β-mannosidosis, fucosidosis, and sialidosis. In The Metabolic and Molecular Bases of Inherited Disease (Scriver, C.R, Beaudet, A.L., Sly, W.S and Valle, D., eds), pp. 3507-3534, McGraw Hill, New York
19. de Geest, N., Bonten, E., Mann, L., de Sousa-Hitzler, J., Hahn, C. and d'Azzo, A. (2002) Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice. Hum. Mol. Genet. 11, 1455-1464
20. Yogalingam, G., Bonten, E.J., van de Vlekkert, D., Hu, H., Moshiach, S., Connell, S.A. and d'Azzo, A. (2008) Neuraminidase 1 is a negative regulator of lysosomal exocytosis. Dev. Cell 15, 74-86
21. Wu, X., Steigelman, K.A., Bonten, E., Hu, H., He, W., Ren, T., Zuo, J. and d'Azzo, A. (2010) Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1-deficient mice. Biochim. Biophys. Acta 1802, 259-268
22. Zanoteli, E., de Vlekkert, D.V., Bonten, E.J., Hu, H., Mann, L., Gomero, E.M., Harris, A.J., Ghersi, G. and d'Azzo, A. (2010) Muscle degeneration in neuraminidase 1-deficient mice results from infiltration of the muscle fibers by expanded connective tissue. Biochim. Biophys. Acta 1802, 659-672
23. Suzuki, Y., Oshima, A. and Nanba, E. (2001) β-Galactosidase deficiency (β-galactosidosis): GM1 gangliosidosis and Morquio B disease. In The Metabolic and Molecular Bases of Inherited Disease (Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D., eds), pp. 3775-3810, McGraw-Hill, New York
24. d'Azzo, A. (2002) Protective protein cathepsin A (PPCA). In Wiley Encyclopedia of Molecular Medicine (Kazazian, H.H., Klein, G., Moser, H.W., Orkin, S.H., Roizman, B., Thakker, R.V., Watkins, H., eds), pp. 2624-2628, John Wiley and Sons, Chichester
25. Hahn, C., Martin, M., Schröder, M., Vanier, M., Hara, Y., Suzuki, K., Suzuki, K. and d'Azzo, A. (1997) Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid β-galactosidase. Hum. Mol. Genet. 6, 205-211
26. Yamashita, T., Wu, Y.P., Sandhoff, R., Werth, N., Mizukami, H., Ellis, J.M., Dupree, J.L., Geyer, R., Sandhoff, K. and Proia, R.L. (2005) Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc. Natl. Acad. Sci. U.S.A. 102, 2725-2730
27. Tessitore, A., del P. Martin, M., Sano, R., Ma, Y., Mann, L., Ingrassia, A., Laywell, E.D., Steindler, D.A., Hendershot, L.M. and d'Azzo, A. (2004) GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol. Cell 15, 753-766
28. Sano, R., Annunziata, I., Patterson, A., Moshiach, S., Gomero, E., Opferman, J., Forte, M. and d'Azzo, A. (2009) GM1-ganglioside at the mitochondria-associated ER membranes links ER stress to mitochondrial apoptosis. Mol. Cell 36, 500-511
29. Beck, M. (2007) New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum. Genet. 121, 1-22
30. Hahn, C., Martin, M., Zhou, X., Mann, L. and d'Azzo, A. (1998) Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter. Proc. Natl. Acad. Sci. U.S.A. 95, 14880-14885
31. Bonten, E.J., Wang, D., Toy, J.N., Mann, L., Mignardot, A., Yogalingam, G. and d'Azzo, A. (2004) Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis. FASEB J. 9, 971-973
32. Wang, D., Bonten, E.J., Yogalingam, G., Mann, L. and d'Azzo, A. (2005) Short-term, high dose enzyme replacement therapy in sialidosis mice. Mol. Genet. Metab. 85, 181-189
33. Elliot-Smith, E., Speak, A.O., Lloyd-Evans, E., Smith, D.A., van der Spoel, A.C., Jeyakumar, M., Butters, T.D., Dwek, R.A., d'Azzo, A. and Platt, F.M. (2008) Beneficial effects of substrate reduction therapy in a mouse model of GM1-gangliosidosis. Mol. Genet. Metab. 94, 204-211
34. Sano, R., Tessitore, A., Ingrassia, A. and d'Azzo, A. (2005) Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. Blood 106, 2259-2268
35. Jeyakumar, M., Thomas, R., Elliot-Smith, E., Smith, D.A., van der Spoel, A.C., d'Azzo, A., Perry, V.H., Butters, T.D., Dwek, R.A. and Platt, F.M. (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2-gangliosidosis. Brain 126, 974-987